Paolo Carta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Paolo Carta has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
E. Bertoni
Nephrology unit Careggi University Hospital, Florence, Italy
9 shared publicationsL. Di Maria
Nephrology Unit, Careggi University Hospital, Florence, Italy
9 shared publications- Maria Zanazzi
Careggi University Hospital, Nephrology Unit, Florence, Italy
8 shared publications - L. Caroti
Nephrology unit Careggi University Hospital, Florence, Italy
5 shared publications Leonardo Caroti
Careggi University Hospital, Florence, Italy
5 shared publicationsLorenzo Di Maria
Careggi University Hospital, Florence, Italy
5 shared publications
Latest Publications
- Open Access
- 9 June 2020
- Published by Troika Publisher Co., Limited in Journal of Renal and Hepatic Disorders
- Vol. 4 (2) , 61-66
Histological Evaluation of Extended Criteria Donors: Donor’s Kidney Biopsy and Graft Outcome after 5 Years of Transplantation
Pre-transplant kidney biopsy is routinely used to decide whether kidneys from marginal donors should be transplanted as single or double trans-plantation. This is a 5-year extension of the follow-up of a previous study. In that study, graft outcomes were compared retrospectively between a group of 44 recipients of a single kidney graft from an extended criteria donor and a Karpinski histological score of 3 or less, and another group of 56 recipients of a single transplant with a Karpinski histological score of 4 or 5. After 5 years of transplantation, there was no difference between the two groups in terms of recipient’s serum creatinine levels (1.8 ± 0.5 vs 1.9 ± 0.6 mg/dL, P = 0.5), creatinine clearance (53 ± 23 vs 49 ± 27.0 mL/min, P = 0.6), or the rates of graft loss (41% vs 49%,P = 0.5). Therefore, the choice between single and double transplant should not be made only on the basis of histological score but should be done together with the evaluation of donor’s clinical parameters, especially the renal function.
- 9 June 2020
- Published by Troika Publisher Co., Limited in Journal of Renal and Hepatic Disorders
- Vol. 4 (2) , 61-66
Open AccessHistological Evaluation of Extended Criteria Donors: Donor’s Kidney Biopsy and Graft Outcome after 5 Years of Transplantation
Pre-transplant kidney biopsy is routinely used to decide whether kidneys from marginal donors should be transplanted as single or double trans-plantation. This is a 5-year extension of the follow-up of a previous study. In that study, graft outcomes were compared retrospectively between a group of 44 recipients of a single kidney graft from an extended criteria donor and a Karpinski histological score of 3 or less, and another group of 56 recipients of a single transplant with a Karpinski histological score of 4 or 5. After 5 years of transplantation, there was no difference between the two groups in terms of recipient’s serum creatinine levels (1.8 ± 0.5 vs 1.9 ± 0.6 mg/dL, P = 0.5), creatinine clearance (53 ± 23 vs 49 ± 27.0 mL/min, P = 0.6), or the rates of graft loss (41% vs 49%,P = 0.5). Therefore, the choice between single and double transplant should not be made only on the basis of histological score but should be done together with the evaluation of donor’s clinical parameters, especially the renal function.
- Open Access
- 12 May 2020
- Published by Troika Publisher Co., Limited in Journal of Renal and Hepatic Disorders
- Vol. 4 (1) , 31-34
Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
Hepatitis C virus (HCV) causes increased mortality and morbidity in kidney transplant patients. Interferon-based therapies are poorly tolerated and involve the risk of rejection. The new direct-acting antiviral drugs (DAAs) have revolutionized the treatment of HCV infection in transplant patients. This observational study evaluates changes in immunosuppressive therapy during treatment with DAA in renal transplant recipients.In our transplant center, we selected seven HCV-positive patients at the time of transplantation , four men and three women, with an average age of 61 ± 7 years, in therapy with DAA. The dose and the blood levels of the immunosuppressive drugs were evaluated at the beginning and end of antiviral therapy, together with creatinine and proteinuria.Viremia was negativized in all patients within the initial 8 weeks of therapy. Currently, the number of patients is too limited to perform a sta-tistical analysis and obtain significant results. In one patient, the dose of Cyclosporine was lowered to 10 mg, while for the remaining patients it was not necessary to change the dose of immunosuppressive drugs.DAAs give encouraging results in the eradication of HCV in renal transplant recipients, although they are associated with potential adverse drug interactions. The preliminary data of our study suggest that it is not necessary to change the dose of immunosuppressive drugs during therapy and that creatinine and proteinuria remain stationary. We will achieve more significant results in the future, adding more patients to our study. However, further randomized trials are necessary to confirm the safety of DAAs.
- 12 May 2020
- Published by Troika Publisher Co., Limited in Journal of Renal and Hepatic Disorders
- Vol. 4 (1) , 31-34
Open AccessInteractions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
Hepatitis C virus (HCV) causes increased mortality and morbidity in kidney transplant patients. Interferon-based therapies are poorly tolerated and involve the risk of rejection. The new direct-acting antiviral drugs (DAAs) have revolutionized the treatment of HCV infection in transplant patients. This observational study evaluates changes in immunosuppressive therapy during treatment with DAA in renal transplant recipients.In our transplant center, we selected seven HCV-positive patients at the time of transplantation , four men and three women, with an average age of 61 ± 7 years, in therapy with DAA. The dose and the blood levels of the immunosuppressive drugs were evaluated at the beginning and end of antiviral therapy, together with creatinine and proteinuria.Viremia was negativized in all patients within the initial 8 weeks of therapy. Currently, the number of patients is too limited to perform a sta-tistical analysis and obtain significant results. In one patient, the dose of Cyclosporine was lowered to 10 mg, while for the remaining patients it was not necessary to change the dose of immunosuppressive drugs.DAAs give encouraging results in the eradication of HCV in renal transplant recipients, although they are associated with potential adverse drug interactions. The preliminary data of our study suggest that it is not necessary to change the dose of immunosuppressive drugs during therapy and that creatinine and proteinuria remain stationary. We will achieve more significant results in the future, adding more patients to our study. However, further randomized trials are necessary to confirm the safety of DAAs.
- Open Access
- 12 May 2020
- Published by Troika Publisher Co., Limited in Journal of Renal and Hepatic Disorders
- Vol. 4 (1) , 18-21
Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients?
Tacrolimus (FK506) is the most widely used anti-rejection drug in kidney transplantation, especially its extended release Tacrolimus formulation (ER-Tac, Advagraf), which is used when target blood levels can be difficult to reach in high metabolizer patients. In this retrospective monocentric study, we analyzed the effect of a switch from ER-Tac to LifeCycle Pharma Tacrolimus (LPCT, Envarsus) on the dose/level ratio of FK506 in high metabolizer patients that cannot achieve target blood levels in the first 6 months after transplantation.We observed a statistically significant improvement in the level to dose ratio after the switch. Renal function remained stable. We also observed a reduction in the development of tremors. Our data suggest that LPCT can be used in a safer way in high metabolizer kidney transplant recipients.
- 12 May 2020
- Published by Troika Publisher Co., Limited in Journal of Renal and Hepatic Disorders
- Vol. 4 (1) , 18-21
Open AccessConversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients?
Tacrolimus (FK506) is the most widely used anti-rejection drug in kidney transplantation, especially its extended release Tacrolimus formulation (ER-Tac, Advagraf), which is used when target blood levels can be difficult to reach in high metabolizer patients. In this retrospective monocentric study, we analyzed the effect of a switch from ER-Tac to LifeCycle Pharma Tacrolimus (LPCT, Envarsus) on the dose/level ratio of FK506 in high metabolizer patients that cannot achieve target blood levels in the first 6 months after transplantation.We observed a statistically significant improvement in the level to dose ratio after the switch. Renal function remained stable. We also observed a reduction in the development of tremors. Our data suggest that LPCT can be used in a safer way in high metabolizer kidney transplant recipients.
- 1 March 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (2) , 337-339
Anemia and Immunosuppressive Regimen in Renal Transplanted Patients: Single-Center Retrospective Study
- 1 March 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (2) , 337-339
Anemia and Immunosuppressive Regimen in Renal Transplanted Patients: Single-Center Retrospective Study
- 1 July 2015
- Published by Elsevier in Transplantation Reviews
- Vol. 29 (3) , 135-138
Anti-human leukocyte antigen DQ antibodies in renal transplantation: Are we underestimating the most frequent donor specific alloantibodies?
- 1 July 2015
- Published by Elsevier in Transplantation Reviews
- Vol. 29 (3) , 135-138
Anti-human leukocyte antigen DQ antibodies in renal transplantation: Are we underestimating the most frequent donor specific alloantibodies?
- 11 February 2015
- Published by Frontiers Media SA in Transplant International
- Vol. 28 (3) , 370-372
Unplanned pregnancies in kidney transplanted patients treated with everolimus: three case reports
- 11 February 2015
- Published by Frontiers Media SA in Transplant International
- Vol. 28 (3) , 370-372
Unplanned pregnancies in kidney transplanted patients treated with everolimus: three case reports
- 1 September 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (7) , 2228-2230
5 year Comparison of Very Low-dose Cyclosporine and High-dose Everolimus vs Standard Cyclosporine and Enteric-coated Mycophenolate in Renal Transplantation Patients
- 1 September 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (7) , 2228-2230
5 year Comparison of Very Low-dose Cyclosporine and High-dose Everolimus vs Standard Cyclosporine and Enteric-coated Mycophenolate in Renal Transplantation Patients
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 528
Endothelial Response, Parathyroid Hormone and Homocysteine in Renal Transplant Recipients: 3-Year Follow-Up Data.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 528
Endothelial Response, Parathyroid Hormone and Homocysteine in Renal Transplant Recipients: 3-Year Follow-Up Data.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 571
Unplanned Pregnancies in Kidney Transplanted Patients Treated With Everolimus.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 571
Unplanned Pregnancies in Kidney Transplanted Patients Treated With Everolimus.
- Open Access
- 30 July 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (10) , 2637-2644
Impact of the pre-transplant histological score on 3-year graft outcomes of kidneys from marginal donors: a single-centre study
The reliability of kidney biopsy as the sole means for assessing kidneys from extended-criteria donors (ECDs) to be allocated to single or dual transplantation is still a matter of debate. We compared retrospectively 3 years graft survival and renal function in 44 recipients of a single kidney graft from a marginal donor with good renal function and a Karpinski histological score of ≤3 and 56 recipients of a single transplant with a Karpinski score of 4 or 5. The donors’ and recipients’ characteristics were compared by means of Wilcoxon's rank-sum test and Fisher's exact test, and survival was analysed using the log-rank test and Cox regression survival analysis. The donors with the worse histological scores were slightly younger (68.0 ± 4.74 versus 71.3 ± 4.6 years, P < 0.01) and had a higher glomerular filtration rate (85.8 ± 28.2 versus 76.3 ± 26.53 mL/min, P = 0.013), but there was no difference in serum creatinine levels (0.83 ± 0.24 versus 0.85 ± 0.30 mg/dL, P = 0.381). Three years after transplantation, there was no difference between the two groups in terms of recipient serum creatinine levels (1.94 ± 0.69 versus 1.74 ± 0.49 mg/dL, P = 0.134), estimated glomerular filtration rate (eGFR, 45.6 ± 21.1 versus 51.7 ± 22.0 mL/min, P = 0.331) or the rates of graft loss (27.3 versus 35.7%, P = 0.47), delayed graft function or acute rejection. In our experience, provided the donor has a normal renal function, a difference in the pre-transplant histological score of kidneys from marginal cadaveric donors do not have a significant influence on the outcome 3 years after transplantation. Our findings might represent a basis for designing a randomized controlled trial of using a higher histological score threshold for the DKT allocation of grafts from ECDs with a normal renal function.
- 30 July 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (10) , 2637-2644
Open AccessImpact of the pre-transplant histological score on 3-year graft outcomes of kidneys from marginal donors: a single-centre study
The reliability of kidney biopsy as the sole means for assessing kidneys from extended-criteria donors (ECDs) to be allocated to single or dual transplantation is still a matter of debate. We compared retrospectively 3 years graft survival and renal function in 44 recipients of a single kidney graft from a marginal donor with good renal function and a Karpinski histological score of ≤3 and 56 recipients of a single transplant with a Karpinski score of 4 or 5. The donors’ and recipients’ characteristics were compared by means of Wilcoxon's rank-sum test and Fisher's exact test, and survival was analysed using the log-rank test and Cox regression survival analysis. The donors with the worse histological scores were slightly younger (68.0 ± 4.74 versus 71.3 ± 4.6 years, P < 0.01) and had a higher glomerular filtration rate (85.8 ± 28.2 versus 76.3 ± 26.53 mL/min, P = 0.013), but there was no difference in serum creatinine levels (0.83 ± 0.24 versus 0.85 ± 0.30 mg/dL, P = 0.381). Three years after transplantation, there was no difference between the two groups in terms of recipient serum creatinine levels (1.94 ± 0.69 versus 1.74 ± 0.49 mg/dL, P = 0.134), estimated glomerular filtration rate (eGFR, 45.6 ± 21.1 versus 51.7 ± 22.0 mL/min, P = 0.331) or the rates of graft loss (27.3 versus 35.7%, P = 0.47), delayed graft function or acute rejection. In our experience, provided the donor has a normal renal function, a difference in the pre-transplant histological score of kidneys from marginal cadaveric donors do not have a significant influence on the outcome 3 years after transplantation. Our findings might represent a basis for designing a randomized controlled trial of using a higher histological score threshold for the DKT allocation of grafts from ECDs with a normal renal function.